Clinical Research & Development

Our research and development pipeline is strategically focussed on areas of high unmet clinical need. Chiesi is actively developing novel therapies in respiratory care, rare diseases, and special care, with the goal of delivering meaningful improvements in patient outcomes. Explore our current research and discover how our science is shaping the future of care.​

Research and development at Chiesi

Our pipeline products are currently focused in three key areas: respiratory, rare disease and special care.

• Respiratory – As well as seeking to improve on our existing products, we are currently researching multi-modal inhalers for diseases such as chronic obstructive pulmonary disease and investigating drug candidates to combine with our innovative drug delivery platform of formulation and inhaler device technologies. These programmes include novel anti-inflammatory, bronchodilator and anti-fibrotic agents as well as other molecules. We are also committed to improving outcomes and addressing other unmet needs in neonatal respiratory disease.
• Rare disease – Our pipeline in the rare disease space has focused largely on targeted enzyme replacement therapies to treat lysosomal storage disorders. However, we are also investigating candidates in haematology and ophthalmology.
• Special care – We are committed to improving care for those with specific, chronic conditions. Our research in this area is predominantly in the cardiovascular field with lifecycle management of licensed products.

Clinical pipeline